Literature DB >> 22167570

Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.

M K DeGorter1, B L Urquhart, U Gradhand, R G Tirona, R B Kim.   

Abstract

Response to statin therapy is often unpredictable because of variability in metabolism and transport. In the recently created organic anion transporting-polypeptide 1b2 (Oatp1b2/Slco1b2)-null mice, the investigators found significantly lower liver-to-plasma ratios compared with controls for atorvastatin (16.0 ± 5.1 vs 43.5 ± 13.7, P = .002) and rosuvastatin (15.2 ± 3.3 vs 28.4 ± 9.3, P = .03), but not simvastatin (5.2 ± 1.1 vs 6.3 ± 2.9, P = .49), following tail vein injection of 1 mg/kg of each drug. In addition, the investigators examined intraindividual variation in atorvastatin, rosuvastatin, and simvastatin pharmacokinetics in healthy human subjects in a crossover study design. Areas under the plasma concentration-time curve of atorvastatin and simvastatin acid were significantly related (Spearman r = 0.68; P = .035), whereas rosuvastatin profile was not related to atorvastatin or simvastatin exposure. Together, these results in mice and humans demonstrate that predictability of exposure to one statin based on another is dependent on the specific statin pairs and the context in which they are compared.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22167570     DOI: 10.1177/0091270011422815

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression.

Authors:  John D Clarke; Rhiannon N Hardwick; April D Lake; Mark J Canet; Nathan J Cherrington
Journal:  J Pharmacol Exp Ther       Date:  2014-01-08       Impact factor: 4.030

2.  Mouse NTCP-Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice.

Authors:  Laura E Russell; Marianne K DeGorter; Richard H Ho; Brenda F Leake; Crystal L Schmerk; Sara E Mansell; Richard B Kim
Journal:  AAPS J       Date:  2021-01-06       Impact factor: 4.009

3.  A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.

Authors:  Priyanka Kulkarni; Ken Korzekwa; Swati Nagar
Journal:  Xenobiotica       Date:  2019-10-01       Impact factor: 1.908

4.  Prediction of Cyclosporin-Mediated Drug Interaction Using Physiologically Based Pharmacokinetic Model Characterizing Interplay of Drug Transporters and Enzymes.

Authors:  Yiting Yang; Ping Li; Zexin Zhang; Zhongjian Wang; Li Liu; Xiaodong Liu
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

5.  Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.

Authors:  Marianne K DeGorter; Rommel G Tirona; Ute I Schwarz; Yun-Hee Choi; George K Dresser; Neville Suskin; Kathryn Myers; GuangYong Zou; Otito Iwuchukwu; Wei-Qi Wei; Russell A Wilke; Robert A Hegele; Richard B Kim
Journal:  Circ Cardiovasc Genet       Date:  2013-07-22

6.  Scutellarin is Highly Likely to be Responsible for Drug-Drug Interactions Mediated by Hepatic Organic Anion-Transporting Polypeptide1B3.

Authors:  Jianming Liu; Yongmei Guo; Yanqi Xu; Li Yuan; Huiting Zhu
Journal:  Pharm Res       Date:  2020-10-29       Impact factor: 4.200

Review 7.  Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making.

Authors:  Javier Reig-López; Alfredo García-Arieta; Víctor Mangas-Sanjuán; Matilde Merino-Sanjuán
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.